Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x100px

Product › Details

Erbitux®

	Next higher product group	cetuximab
	Status	2004-07-01 sales start
	Annual sales	USD 2,016,000,000 (sales (2013) 2013)
	Organisation	Merck KGaA
	Group	Merck (DE) (Group)
	Organisation 2	ImClone Systems Inc.
	Group	Eli Lilly (Group)

Record changed: 2024-01-07

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for antibody cancer drug

[1] Antiverse Ltd.. (10/16/23). "Press Release: Antiverse and GlobalBio, Inc. Extend Collaboration to Advance Antibody Cancer Therapeutics". Cardiff & Cambridge, MA....
[2] Macomics Ltd.. (3/23/23). "Press Release: Macomics and Ono Pharmaceutical Partner to Discover and Develop Macrophage-targeting Antibody Therapy"....
[3] UCB S.A.. (3/9/23). "Press Release: Cancer Research UK Signs Multi-Project Collaboration with UCB to Advance Oncology Antibody Candidates". Brussels & London....
[4] MorphoSys AG. (6/14/22). "Press Release: MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210". Planegg & South San Francisco, CA....
[5] Recordati Industria Chimica e Farmaceutica S.p.A.. (12/3/21). "Press Release: Recordati to Acquire EUSA Pharma (UK) Ltd., a Global Specialty Pharmaceutical Company Focused on Rare and Niche Oncology Diseases". Milan....
[6] SynOx Therapeutics Ltd.. (7/27/21). "Press Release: SynOx Therapeutics Strengthens Team with Appointment of Ton Logtenberg as Chairman and Ray Barlow as Chief Executive Officer". Dublin....
[7] iTeos Therapeutics Inc.. (6/14/21). "Press Release: iTeos Therapeutics and GSK Announce Development and Commercialisation Collaboration for EOS-448, an anti-TIGIT Monoclonal Antibody, Enabling Novel Next-generation Immuno-oncology Combinations". Gosselie...
[8] Alligator Bioscience AB. (3/18/21). "Press Release: Alligator Bioscience Appoints Søren Bregenholt as New CEO". Lund....
[9] Novartis AG. (1/11/21). "Press Release: Novartis Expands Oncology Pipeline with In-licensing of Tislelizumab from BeiGene". Basel....
[10] Merus N.V.. (1/7/21). "Press Release: Merus Granted FDA Fast Track Designation of Zenocutuzumab for the Treatment of Patients with Neuregulin 1 Fusion Cancers". Utrecht & Cambridge, MA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)